We are live on ! Find out more
MBRX icon

Moleculin Biotech
MBRX

15 hedge funds and large institutions have $918K invested in Moleculin Biotech in 2017 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 3 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,000% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 1

331% more capital invested

Capital invested by funds: $213K → $918K (+$705K)

150% more funds holding

Funds holding: 6 → 15 (+9)

0% more ownership

Funds ownership: 0% → 0% (+0%)

Holders
15
Holders Change
+9
Holders Change %
+150%
% of All Funds
0.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
3
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$381K
2
VKH
Virtu KCG Holdings
New York
+$364K
3
SM
Sabby Management
Florida
+$154K
4
TSS
Two Sigma Securities
New York
+$38.5K
5
Truist Financial
Truist Financial
North Carolina
+$31.5K

Top Sellers

Rank Fund Capital Flow
1
Citigroup
Citigroup
New York
-$17K
2
NFG
Next Financial Group
Texas
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$309K +$381K +109 +1,363%
VKH
2
Virtu KCG Holdings
New York
$274K +$364K +104 New
SM
3
Sabby Management
Florida
$117K +$154K +44 New
Truist Financial
4
Truist Financial
North Carolina
$47K +$31.5K +9 +100%
Bank of America
5
Bank of America
North Carolina
$29K – – –
TSS
6
Two Sigma Securities
New York
$28K +$38.5K +11 New
BlackRock
7
BlackRock
New York
$21K +$28K +8 New
Citadel Advisors
8
Citadel Advisors
Florida
$20K +$28K +8 New
Goldman Sachs
9
Goldman Sachs
New York
$20K +$28K +8 New
Morgan Stanley
10
Morgan Stanley
New York
$13K +$17.5K +5 New
Northern Trust
11
Northern Trust
Illinois
$13K +$17.5K +5 New
WS
12
Wedbush Securities
California
$12K +$14K +4 New
UBS Group
13
UBS Group
Switzerland
$7K +$7K +2 +200%
TRCT
14
Tower Research Capital (TRC)
New York
$4K +$3.5K +1 New
AIM
15
Acrospire Investment Management
Illinois
$3K +$3.5K +1 New
AWMS
16
Advocacy Wealth Management Services
Georgia
$1K – – –
Citigroup
17
Citigroup
New York
– -$17K -3 Closed
NFG
18
Next Financial Group
Texas
– -$1K – –

MBRX Hedge Fund Activity: Q1 2017 in Review

15 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q1 2017, worth a combined $918K — up 331% from $213K a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new MBRX positions and 1 closed out — a net gain of 10 holders — while 3 added to existing stakes and 0 trimmed.

The largest buyer was Vanguard Group, adding an estimated $381K. The largest seller was Citigroup, exiting entirely with an estimated $17K sold.

  • 15 institutional investors held Moleculin Biotech (MBRX) as of Q1 2017, up from 6 in Q4 2016.
  • Funds reported $918K of Moleculin Biotech stock for Q1 2017, up 331% quarter-over-quarter.
  • 11 funds opened new Moleculin Biotech positions in Q1 2017 and 1 closed out, a net change of +10 holders.
  • The largest Moleculin Biotech buyer in Q1 2017 was Vanguard Group, an estimated $381K added.
  • The largest Moleculin Biotech seller in Q1 2017 was Citigroup, an estimated $17K sold.

Based on aggregated 13F filings for Q1 2017.